Cited by 103Mesenchymal stem cell researchAngiogenesis and VEGF in CancerTissue Engineering and Regenerative Medicine

Hypoxia Pretreatment of Bone Marrow Mesenchymal Stem Cells Facilitates Angiogenesis by Improving the Function of Endothelial Cells in Diabetic Rats with Lower Ischemia

Open access
Liu, Jiejie, Hao, Haojie, Xia, Lei, Ti, Dongdong, Huang, Hong, Dong, Liang, Tong, Chuan, Hou, Qian +4 more·2015·PLOS ONE

Abstract

Endothelial dysfunction induced by unordered metabolism results in vascular reconstruction challenges in diabetic lower limb ischemia (DLLI). Mesenchymal stem cells (MSCs) are multipotent secretory cells that are suitable for clinical DLLI treatment, but their use has been hampered by poor survival after injection. Hypoxia can significantly enhance the capacity of MSCs to secrete angiogenic factors. We investigated transient hypoxia pretreatment of MSCs to facilitate revascularization in DLLI. Rat bone marrow MSCs (BM-MSCs) were cultured at different oxygen concentrations for varying time periods. The results indicated that transient pretreatment (5% O2, 48 h) not only increased the expression of VEGF-1α, ANG, HIF-1α and MMP-9 in BM-MSCs as assessed by real-time RT-PCR, but also increased the expression of Bcl-2 as determined by western blotting. The transplantation of pretreated BM-MSCs into rats with DLLI demonstrated accelerated vascular reconstruction when assayed by angiography and immunohistochemistry. CM-Dil-labeled tracer experiments indicated that the survival of BM-MSCs was significantly improved, with approximately 5% of the injected cells remaining alive at 14 days. The expression levels of VEGF-1α, MMP-9 and VEGF-R were significantly increased, and the expression of pAKT was up-regulated in ischemic muscle. Double immunofluorescence studies confirmed that the pretreated BM-MSCs promoted the proliferation and inhibited the apoptosis of endothelial cells. In vitro, pretreated BM-MSCs increased the migratory and tube forming capacity of endothelial cells (ECs). Hypoxia pretreatment of BM-MSCs significantly improved angiogenesis in response to tissue ischemia by ameliorating endothelial cell dysfunction and is a promising therapeutic treatment for DLLI.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0126715

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Liu, J., Hao, H., Xia, L., Ti, D., Huang, H., Dong, L., Tong, C., Hou, Q., Zhao, Y., Liu, H., Fu, X., & Han, W.
Affiliations
Chinese PLA General Hospital (CN)
Corresponding author
  • Fu, Xiaobing
  • Han, Weidong
Venue
PLOS ONE
Published
2015-05-21
Volume
10
Issue
5
Pages
e0126715
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1506316383
Cited by
101
References
37
Citations by year
2026: 4 · 2025: 4 · 2024: 12 · 2023: 13 · 2022: 11 · 2021: 7 · 2020: 14 · 2019: 6 · 2018: 10 · 2017: 7 · 2016: 10 · 2015: 3
FWCI
5.60
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
National Natural Science Foundation of China (2012CB518105, 81121004, 81230041, 2013AA020105, 2012AA020502, 2012CB518103)
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
Keywords
bone marrow mesenchymal stem cells, angiogenesis, endothelial dysfunction, revascularization, HIF-1α, MMP-9, Bcl-2, cell survival after transplantation, Akt signaling, angiogenic factors
MeSH terms
Angiography, Animals, Hypoxia, Cell Survival, Cells, Cultured, Diabetes Mellitus, Experimental, Disease Models, Animal, Humans, Ischemia, Male, Neovascularization, Pathologic, Ultrasonography, Signal Transduction, Apoptosis, Lower Extremity, Vascular Endothelial Growth Factors, Endothelial Cells, Angiogenesis Inducing Agents, Mesenchymal Stem Cell Transplantation, Proto-Oncogene Proteins c-akt, Rats, Mesenchymal Stem Cells, Human Umbilical Vein Endothelial Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review